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Abstract
Background: Vinca alkaloids are an important class of anticancer agents and semisynthetic vinca
alkaloids are developed to improve the therapeutic index of this class of drugs. In the present study,
a direct comparison was made between vinflunine and vinorelbine regarding their radiosensitising
and cell cycle effects.
Methods: Four human tumour cell lines were tested under identical experimental conditions,
using equitoxic concentrations of vinflunine and vinorelbine.
Results: Vinflunine and vinorelbine induced a comparable radiosensitising effect (p-value never
below 0.01) when cells were incubated for 24 h immediately prior to radiation. Regarding the cell
cycle effects, a statistically significant concentration-dependent G2/M block was seen after 24 h
incubation with vinorelbine in all tested cell lines. Similar results, with small cell line-related
differences, were observed with vinflunine.
Conclusion: The radiosensitising effects of both semisynthetic vinca alkaloids were comparable
(not statistically different) and nearly always cell line-specific and concentration-dependent. The cell
cycle effects could be related to the observed radiosensitising effects. Considering the more
favourable toxicity profile of vinflunine, this agent might be more promising than vinorelbine for
chemoradiation studies in the clinic.
Background
Vinca alkaloids are an important class of antitumour
agents used in chemotherapy, either as single agents or in
combination regimens. Semisynthetic vinca alkaloids,
such as vinorelbine (VRL) and most recently vinflunine
(VFL), have been developed to improve the therapeutic
index [1]. Like the other vinca alkaloids, VRL and VFL
exert their antitumour effect by binding to tubulin, the
major component of microtubules in mitotic spindles.
They diminish microtubule dynamics and assembly,
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which ultimately results in cell cycle arrest at the met-
aphase/anaphase transition [2,3]. However, they also dif-
fer from the naturally occurring vinca alkaloids in
chemical structure, microtubule selectivity, and toxicity.
In that respect, the capacity of VRL to bind preferentially
to mitotic rather than axonal microtubules may imply
that occurrence of neurotoxicity is less likely with VRL
than with vinblastine or vincristine, and may predict a
wider therapeutic window for VRL [4]. VFL also displays
some differences in the interaction with microtubules,
compared to all the other vinca alkaloids, which may lead
to different effects on cell cycle progression and cell death
[5-7]. In the clinic, both VRL and VFL have demonstrated
activity i.e. in the treatment of non-small cell lung
(NSCLC), metastatic breast (MBC) and bladder cancer [8-
13].
Vinflunine versus vinorelbine
Although VFL has a structure close to that of VRL, the
selective introduction of the two fluorine atoms seemed
to influence the drugs characteristics:
- VFL's potency with respect to both inhibition of cell pro-
liferation and mitotic block is lower than that of VRL [6].
VFL exhibits a relatively low in vitro cytotoxic potency, but
has shown superior in vivo activity against a series of
murine and human tumour experimental models [14-16].
These data may suggest a wider spectrum of activity for
VFL and studies are underway to evaluate if this enhanced
efficacy can be translated into an improved spectrum of
clinical activity for VFL [16].
- VFL also has a 3–16 fold lower overall binding affinity
for tubulin than VRL [17]. The lower affinity of VFL may
explain, at least in part, the high concentrations of the
drug needed to block mitosis and cell proliferation [18].
These findings do not explain the relatively high therapeu-
tic efficacy of VFL. However, the therapeutic index of a
drug with a relatively weak potency may be broader than
that of an extremely potent drug [6]. In this context, the
NMR study of Fabre et al. [19] revealed the presence of
specific binding sites and showed a different affinity of
VFL and VRL to the tubulin dimer at physiological temper-
atures. This could account for their different toxicity, and
not necessary implies a different mechanism of action
between these compounds, and is in agreement with in
vivo and in vitro observations.
- The peak intracellular drug concentrations at the mitotic
IC50-value are highest for VFL (4.2 ± 0.2 µM vs 1.3 ± 0.1
µM for VRL). This suggests that intracellular binding reser-
voir(s) may be partially responsible for VFL's high effi-
cacy, by providing a reservoir for excess drug and enabling
its gradual release [6]. VFL also induces significantly
smaller spirals (tubulin aggregates) than VRL and demon-
strates shorter relaxation times compared with VRL [17].
This lower overall binding affinity for tubulin, together
with the smaller spirals, the shorter relaxation times and
the gradual release, suggest that VFL may demonstrate
reduced neurotoxicity relative to VRL [17].
- Finally, VFL seems to be a far less potent inducer of drug
resistance relative to VRL [15,20].
Chemoradiation
There is increasing interest in the combined use of chem-
otherapy and radiotherapy in the clinic for various
tumour types, such as NSCLC, head and neck, oesopha-
geal and cervical cancer [21-25]. Improved outcomes in
patients are most likely a result of increased systemic and
local tumour control, and from a direct interaction
between cytotoxic agents and radiation. This latter aspect
should preferably be investigated in vitro first in order to
optimise the clinical application of the combination.
The  in vitro ability of VRL to potentiate radiation was
already evaluated in several human NSCLC cell lines
(NCI-H460, A549 & PC9) [26,27], SCLC cells (SBC-3)
[28], and head & neck carcinoma cell lines [29]. The
results were cell line-dependent, and showed an additive
effect or a dose-dependent potentiation of radiation. In a
previous study, we investigated the in vitro ability of VFL
to potentiate radiation in 4 different human tumour cell
lines (bladder, head & neck, breast and lung tumour cell
lines). A dose-dependent radiosensitising effect was
shown after 24 h treatment with VFL immediately prior to
radiation, in all cell lines [30].
In the current study, the radiosensitising and cell cycle
effects of VFL and VRL are compared, using the same set of
4 human tumour cell lines and identical experimental
conditions for both drugs. In this manner, the radiosensi-
tising effect of vinflunine can be placed in a more identi-
fiable context.
Methods
Cell lines
Four different human tumour cell lines were used in this
study: ECV304, an epidermoid bladder cancer cell line;
CAL-27, a squamous cell carcinoma cell line of the
tongue; MCF-7, a breast cancer cell line; and H292, a
mucoepidermoid NSCLC cell line. ECV304 cells were cul-
tured in Medium 199 (Invitrogen, Merelbeke, Belgium);
CAL-27 and MCF-7 cells in DMEM medium (Invitrogen),
supplemented with 2 mM glutamine (Invitrogen); and
H292 cells in RPMI-1640 medium (Invitrogen), supple-
mented with 2 mM glutamine and 1 mM sodium pyruvate
(Invitrogen). All media were completed with 10% foetal
calf serum (Invitrogen), no antibiotics were added. Cul-BMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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tures were maintained in exponential growth at 37°C in a
humidified 5% CO2 atmosphere.
Vinorelbine and vinflunine
VRL and VFL were kindly provided by the 'Institut de
Recherche Pierre Fabre', Boulogne, France. For VRL, each
vial consisted of 1 ml containing 10 mg free base in solu-
tion (i.e. 10 mg/ml); for VFL, each vial consisted of 2 ml
containing 50 mg free base in solution (i.e. 25 mg/ml).
Both VRL and VFL were diluted in sterile normal saline
(0.9% NaCl) to make a stock solution of 3 µM and 30 µM
respectively, and were stored at 4°C (no longer than 2
months). Before use, the stock solutions were further
diluted in 0.9% NaCl to the desired concentration.
Cytotoxicity and chemoradiation experiments
Cells were harvested from exponential phase cultures (at
50–75% confluence) by trypsinisation, counted and
plated at optimal seeding densities in 48-well plates to
assure exponential growth during the experiments. Seed-
ing densities were about 1200, 2000, 2200 & 2800 cells/
well in the cytotoxicity experiments and about 250, 100,
150 & 120 cells/well in the chemoradiation experiments,
for ECV304, CAL-27, H292, and MCF-7, respectively.
After a 24 h recovery period, cells were treated during 24
h with VRL or VFL. For determining the cytotoxic effect, a
concentration range of both compounds was tested (0–80
nM VRL/0–400 nM VFL, dissolved in 0.9% NaCl). After
the incubation period, cells were washed with drug free
medium and cell survival was determined by the sul-
forhodamine B (SRB) assay 4 days after the start of treat-
ment. In the chemoradiation experiments, cells were
treated with specified concentrations of VRL or VFL (see
Table 1) and this was immediately followed by radiation
(Cobalt-60 γ rays, 0–8 Gy, room temperature). Experi-
ments were started with low VFL concentrations and these
were increased until a clear radiosensitising effect was
observed. For VRL, about equitoxic concentrations were
applied. After radiation, cells were washed with drug free
medium and incubated at 37°C for 7 or 8 days (about 6
doubling times). Cell survival was determined again by
the SRB assay, a reliable assay in these circumstances, as
described previously [31].
0.9% NaCl alone was added to control cells. Each concen-
tration was tested 6 times within the same experiment and
all experiments were performed at least 3 times. The SRB
assay was performed according to the method of Skehan
et al. and Papazisis et al. [32,33], with minor modifica-
tions [30].
Cell cycle experiments
Exponential growing cells (at 50–75% confluence) were
trypsinised, counted and plated in 6-well plates. In order
to assure exponential growth during the experiments,
seeding densities were about 75 000 cells/well for the first
set of experiments, and about 50 000 cells/well for the cell
cycle kinetics experiments. After at least a 24 h recovery
period, two different cell cycle experiments were per-
formed as follows:
- Firstly, the effect of VRL or VFL on the cell cycle was
investigated. For these experiments, cells were incubated
for 24 h with specified concentrations of VRL or VFL (0–
50 nM/0–400 nM) and flow cytometry was performed
immediately after incubation.
- Secondly, the cell cycle was investigated over time (cell
cycle kinetics). For these experiments, not only different
incubation times were investigated (4 – 48 h), but also
different time points after a 24 h incubation (3 – 72 h).
Therefore cells were treated during 24 h with VRL or VFL
and cell cycle analysis was performed 0, 3, 24, 48 or 72 h
after drug wash out (indicated as 24+0, 24+3, 24+24,
24+48, 24+72, respectively). The concentrations used for
this second set of experiments were identical to those
resulting in a clear G2/M block in the first set of experi-
ments with VFL, and their equitoxic VRL concentrations,
i.e. 30 nM VRL/150 nM VFL for ECV304 and H292, 15 nM
VRL/150 nM VFL for MCF-7 and 15 nM VRL/100 nM VFL
for CAL-27 cells.
Cell cycle analysis was performed by flow cytometry, after
DNA staining, according to the Vindelov method [34], as
described previously [30].
Data analysis and statistics
Cytotoxicity and chemoradiation experiments
The survival rates were calculated by: mean optical density
(OD) of treated cells/mean OD of untreated cells × 100%.
The survival curves after treatment with VRL or VFL alone
were fitted according to the sigmoid inhibition model:
exp(survival) = 1-(Cγ/Cγ+IC50γ). The radiation dose-sur-
vival curves were fitted according to the linear-quadratic
model: survival = exp(-αD - βD2), using WinNonlin
(Pharsight, Palo Alto, CA, USA). The radiation dose-sur-
vival curves were corrected for the cytotoxic effect of VRL
or VFL alone. From these dose-survival curves, the follow-
ing parameters were calculated: the IC50, i.e. the concen-
tration VRL or VFL causing 50% growth inhibition; the
ID50, i.e. the radiation dose causing 50% growth inhibi-
tion; and the mean inactivation dose (MID), which was
calculated by numerical integration of the linear-quad-
ratic curve [35]. A two-sample t-test was used to investi-
gate significant differences at the level of ID50 and MID
values, between control cells (only irradiated) and cells
treated with the combination of chemo- and radiother-
apy. The same statistical analysis was also performed to
compare equitoxic concentrations of VRL with VFL in the
chemoradiation experiments. Statistical significance wasBMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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defined at the level of p < 0.01. The results are expressed
as mean ± standard error. Radiosensitisation was repre-
sented by the dose enhancement factor (DEF): ID50
(without VRL or VFL)/ID50 (with VRL or VFL). Possible
synergism was determined by calculation of the combina-
tion index (CI) by the Chou and Talalay equation [36],
using CalcuSyn (Biosoft, Cambridge, UK), which can be
used for chemoradiation combinations [37]. The CI quan-
tifies drug interaction in terms of additive effect (CI = 1),
synergism (CI < 1), or antagonism (CI > 1). The CI takes
into account both the potency (IC50 or Dm) and the
shape of the dose-survival curve (m value, signifying the
sigmoidicity of the dose-effect curve). The general equa-
tion for the classic isobologram is given by:
CI = (D)1/(Dx)1 + (D)2/(Dx)2
where (Dx)1 and (Dx)2 are the doses (or concentrations)
for D1 (VRL or VFL) and D2 (radiation) alone, required to
inhibit cell growth by 50%, and (D)1 and (D)2 are the
doses of VRL or VFL and radiation in combination that
also inhibit cell growth by 50% (i.e., isoeffective as com-
pared with the single treatments).
The (Dx)1 or (Dx)2 (for VRL or VFL and radiation) are cal-
culated by the formula:
Dx = Dm [fa/(1-fa)]1/m
Where Dm is the dose required to produce absorbance
readings 50% lower than those of non-treated wells (IC50
or ID50), fa is the fraction affected and m is the slope of
the median-effect plot. The CI values obtained from the
classic (mutually exclusive) isobologram calculations
were used. In short: 1.10 > CI > 0.90, 0.90 > CI > 0.85,
0.85 > CI > 0.70 and 0.70 > CI > 0.30 indicating additivity,
slight synergism, moderate synergism and synergism,
respectively.
Cell cycle experiments
Flow cytometric data were analysed using Cell Quest (Bec-
ton Dickinson). In our experiments, polyploid cell popu-
lations appeared after treatment with both VRL and VFL.
Therefore, besides the normal cell cycle phases G1, S and
G2/M; S2 (second synthesis phase, without previous mito-
sis) and polyploid G2/M ((G2/M)2, cells in G2/M after
S2), with a double DNA content compared to cells in nor-
mal G2/M, were explored.
A 2 sample t-test was used to investigate the significance
of the differences between the percentages of cells in the
different cell cycle phases after treatment with VRL or VFL
versus the untreated cells, 24 h incubation, 24+0 h, and
24+24 h schedule (see previous section for the explana-
tion of the different treatment schedules), and to compare
equitoxic concentrations of VRL with VFL. Statistical sig-
nificance was defined at the level of p < 0.05. The results
are expressed as mean ± standard error.
Results
Cytotoxicity experiments
To investigate and compare the cytotoxic effect of VRL and
VFL, IC50-values were calculated for both drugs. All tested
cell lines were 5–8 times more sensitive to VRL than to
VFL (data not shown). These results enabled us to use
equitoxic concentrations of VRL and VFL to directly com-
pare the radiosensitising and cell cycle effects of these two
compounds.
Chemoradiation experiments
The radiation parameters of the 4 human tumour cell
lines treated with radiation alone or with the combination
of VRL and radiation are summarised in Table 1. The com-
bination of VRL and radiation resulted in more cell kill
compared to the control curves (irradiation only) in all 4
cell lines. In ECV304, radiosensitisation was already seen
at concentrations around IC15 (DEF = 1.49), resulting in
slight synergism using CI calculations. For H292, concen-
trations around IC20 were required (DEF = 1.36) to
observe a moderate synergistic effect, and for CAL-27
cells, concentrations around IC45 (DEF = 1.92) resulted
in clear synergism. With higher VRL concentrations, an
increase in radiosensitivity was observed in all these cell
lines (higher DEFs, accompanied by a decrease of ID50
and MID values). In MCF-7 however, once a radiosensitis-
ing effect was established (from low concentrations on),
the effect was not dose proportional with VRL. The result-
ing DEF (± 1.5) was equal for every tested concentration
(between IC20 and IC55), although CI calculation
showed an increase from an additive effect to moderate
synergism.
The radiation dose-survival curves of VFL have been pre-
sented earlier and indicated a radiosensitising effect in all
tested cell lines [30]. The MID, ID50, DEF and CI-values
for VFL are also summarised in Table 1. The radiosensitis-
ing effect of VFL was most pronounced in ECV304 cells,
already at concentrations around IC10 (moderate syner-
gism). In MCF-7 and H292, radiosensitisation was seen at
concentrations around the IC40 (synergism and moderate
synergism, respectively), while rather toxic concentrations
around IC70 were required in CAL-27 cells to induce a
synergistic effect.
To compare the effects of both VFL and VRL on radiation,
equitoxic concentrations of VRL were used. The data sug-
gest that the radiosensitising effects of VFL and VRL are
comparable, since statistical analysis – performed to com-
pare equitoxic VRL concentrations with VFL – never
reached statistical significant differences (p-value neverBMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
Page 5 of 12
(page number not for citation purposes)
Table 1: Radiation parameters of the four human tumour cell lines, for VRL and VFL; mean values ± standard error.
Cell line Conc. (nM) IC-value* N Mean MID Mean ID50 Mean DEF Mean CI
VRL
ECV304 0 13 3,23 ± 0,14 2.71 ± 0.15
4 IC15 8 2,45 ± 0,24a 1.88 ± 0.23a 1.49 ± 0.13 0.89 ± 0.01 slight synergism
6 IC30 9 2,10 ± 0,21a 1.56 ± 0.16a 1,97 ± 0,26 0,77 ± 0,01 moderate synergism
CAL-27 0 9 3,23 ± 0,12 2.99 ± 0.12
2,5 IC45 9 2,22 ± 0,20a 1.68 ± 0.19a 1,92 ± 0,24 0,69 ± 0,01 synergism
3,5 IC75 8 1,81 ± 0,24a 1.33 ± 0.17a 2,49 ± 0,41 0,51 ± 0,01 synergism
MCF-7 0 19 3.26 ± 0.12 2.80 ± 0.16
3 IC20 17 2.66 ± 0.17a 2.00 ± 0.15a 1.48 ± 0.05 0.93 ± 0,02 additivity
4 IC55 11 2.55 ± 0.28a 1.94 ± 0.21a 1.47 ± 0.10 0.78 ± 0,04 moderate synergism
H292 0 16 3,69 ± 0,10 2.91 ± 0.10
3 IC10 15 3,18 ± 0,18 2.51 ± 0.16 1,19 ± 0,06 0,97 ± 0,02 additivity
4 IC20 5 2,59 ± 0,27a 2.00 ± 0.22a 1,36 ± 0,06 0,83 ± 0,04 moderate synergism
VFL
ECV304 0 5 3.18 ± 0.25 2.46 ± 0.28
30 IC10 5 2.12 ± 0.26 1.56 ± 0.16 1.57 ± 0.11 0.84 ± 0.01 moderate synergism
50 IC25 5 1.66 ± 0.08a 1.26 ± 0.05a 1.93 ± 0.14 0.71 ± 0.01 moderate synergism
CAL-27 0 5 3.24 ± 0.13 2.81 ± 0.17
25 IC40 4 2.48 ± 0.23 2.01 ± 0.26 1.41 ± 0.09 0.98 ± 0.04 additivity
30 IC70 4 1.63 ± 0.06a 1.22 ± 0.05a 2.29 ± 0.23 0.57 ± 0.02 synergism
MCF-7 0 4 4.00 ± 0.34 3.18 ± 0.26
30 IC40 4 3.07 ± 0.38 2.29 ± 0.29 1.42 ± 0.13 0.77 ± 0.01 moderate synergism
40 IC60 4 1.93 ± 0.16a 1.48 ± 0.14a 2.24 ± 0.08 0.54 ± 0.01 synergism
H292 0 4 5.16 ± 0.36 4.42 ± 0.31
30 IC10 4 4.55 ± 0.64 3.55 ± 0.46 1.29 ± 0.14 1.27 ± 0.12 additivity
40 IC40 3 3.60 ± 0.21a 3.03 ± 0.20a 1.53 ± 0.02 0.77 ± 0.03 moderate synergism
N = number of experiments
MID = mean inactivation dose
ID50 = radiation dose causing 50% growth inhibition
DEF = Dose Enhancement Factor
CI = Combination Index
a p < 0.01 compared to control (0 nM VFL)
* IC-value represents the concentration of VRL or VFL causing a specific percentage of inhibition of cell growth
DNA histograms of vinorelbine and vinflunine in ECV304 cells Figure 1
DNA histograms of vinorelbine and vinflunine in ECV304 cells. detailed legend: DNA histograms of ECV304 cells 
treated with equitoxic concentrations of vinorelbine or vinflunine during 4, 24 and 48 hours and 24 and 48 h after drug 
removal. FL-2A = DNA content. Events = number of fluorescent nuclei.
control 4h 24h 48h 24+3 24+24 24+48
ECV304 30 nM VRL
150 nM VFL
*
   : indicates a statistically significant higher amount of G2/M phase cells after VRL treatment compared to VFL, which coincided with a lower percentage of cells in G1 (*).BMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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below 0.01). However, cell line specific and concentra-
tion-dependent differences were noticed. A marked differ-
ence between the two drugs was observed in the MCF-7
cell line, where, contrary to VFL, the radiosensitising effect
of VRL was found to be not concentration-dependent.
However, this did not reach statistical significance (bor-
derline) since the p-value was only 0.08 comparing 4 nM
VRL with 40 nM VFL.
Cell cycle experiments
Figures 1, 2, 3, 4 show representative DNA-histograms of
all tested cell lines after different time points of exposure
to VRL or VFL, and at different time points after drug
removal.
Cell cycle effects after 24 h treatment with vinorelbine or vinflunine
Table 2 summarises the percentages of cells in the differ-
ent phases of the cell cycle (G1, S & G2/M) for all tested
cell lines, treated with a low and a high VRL concentra-
tion, which approximates an equitoxic VFL concentration
of 60 and 150 nM (these VFL concentrations were selected
because they showed a significant G2/M block in these
cell lines in previous experiments). Immediately after 24
h treatment with VRL, a concentration-dependent G2/M
block was observed in all cell lines (Figures 1, 2, 3, 4,
Table 2). In ECV304, a statistically significant G2/M block
was observed with 30 nM VRL (high VRL concentration),
which coincided with a significant decrease of cells in G1
and S phase. No clear cell cycle effect was observed with
lower concentrations. In CAL-27, MCF-7 and H292, a sta-
tistically significant G2/M block was apparent with the
low VRL concentrations, S phase cells were unchanged,
but cells in G1 were decreased. The amount of cells
arrested in G2/M increased with increasing concentration,
although this effect was only moderately expressed in
MCF-7 cells. As in ECV304, these higher VRL concentra-
tions caused statistically significant changes in the
amount of G1 and S phase cells. Similar results were
observed with VFL [30].
By comparing the results of VRL with those of VFL, a sta-
tistically significant higher amount of G2/M phase cells
could be observed in ECV304 cells with 30 nM VRL com-
pared to that observed with the equitoxic 150 nM VFL
dose. The same trend was observed for both concentra-
tions of VRL in H292 cells. Treatment with 15 and 40 nM
VRL resulted in a higher amount of arrested cells in the
G2/M phase than with VFL, which coincides with a lower
percentage of cells in G1 after VRL treatment compared to
VFL. In CAL-27 and MCF-7 cells, no statistical differences
were observed for the cell cycle effects of VRL versus VFL
after 24 h treatment.
Cell cycle kinetics
Table 3 summarises the percentages of cells in the G2/M
phase, after treatment with different incubation times
with VRL or VFL (4 – 48 h of continuous incubation). In
all cell lines, a statistically significant increase in the per-
centage of cells in G2/M was already visible after 4 h incu-
bation with VRL. A maximal G2/M block was reached
after about 16 h incubation in all the tested cell lines. After
this maximum was reached, the amount of arrested G2/M
phase cells remained unchanged, or slightly decreased
towards the 48 h incubation period. In CAL-27, however,
a statistically significant decrease of G2/M blocked cells
was observed with the 48 h incubation, accompanied by
a strong statistically significant increase of cells in the
polyploid population at that time (see below).
Table 4 summarises the percentages of cells in the G2/M
phase of the cell cycle, different hours after drug removal.
3 h after removal of VRL, the percentage of cells in G2/M
decreased significantly in all cell lines (p < 0.05 compared
to 24+0). This release of cells from G2/M coincided with
DNA histograms of vinorelbine and vinflunine in CAL-27 cells Figure 2
DNA histograms of vinorelbine and vinflunine in CAL-27 cells. detailed legend: DNA histograms of CAL-27 cells 
treated with equitoxic concentrations of vinorelbine or vinflunine during 4, 24 and 48 hours and 24 and 48 h after drug 
removal. FL-2A = DNA content. Events = number of fluorescent nuclei.
CAL-27 15 nM VRL
100 nM VFL
control 4h 24h 48h 24+3 24+24 24+48BMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
Page 7 of 12
(page number not for citation purposes)
an increase in the number of cells in G1 (data not shown)
and the polyploid cell cycle (Table 5), and suggested that
the accumulated cells in G2/M had re-entered the cell
cycle with or without mitosis (normal or polyploid cell
cycle). 24 h after VRL removal, a stable cell cycle was
established again (no significant differences anymore
between 24+24 and 24+72) in CAL-27 and MCF-7 cells.
In ECV304, the cell cycle distribution had stabilised 48 h
after drug removal and the amount of G2/M cells reached
control levels again. In H292, it took 72 h or longer to
regain a stable cell cycle distribution.
Similar cell cycle effects were observed using the same
treatment schedules with VFL [30]. Only in ECV304, the
G2/M block after 24 h VRL incubation was more pro-
nounced (as shown above), since the maximal G2/M
arrest was maintained longer with this agent. Three hours
after removal of VRL, the amount of cells in G2/M was
therefore still significantly higher in this cell line com-
pared to VFL. However, in MCF-7 cells, the amount of
cells blocked in G2/M was statistically lower after VRL
treatment (except for the 24 h timepoint) then after VFL
treatment.
Polyploid cell cycle
Table 5 summarises the percentages of cells in the poly-
ploid cell cycle (S2 and (G2/M)2) after 24 h and 48 h of
incubation with VRL or VFL, and after drug removal
(24+24 & 24+48). The results obtained with VRL were
similar to those obtained with VFL. After 24 h and even
more pronounced after 48 h of continuous incubation, a
polyploid cell population was clearly observed in CAL-27
and ECV304 (Figure 1 and 2), and to a lesser degree also
in H292 and MCF-7 (p < 0.05 compared to control). Only
DNA histograms of vinorelbine and vinflunine in MCF-7 cells Figure 3
DNA histograms of vinorelbine and vinflunine in MCF-7 cells. detailed legend: DNA histograms of MCF-7 cells treated 
with equitoxic concentrations of vinorelbine or vinflunine during 4, 24 and 48 hours and 24 and 48 h after drug removal. FL-2A 
= DNA content. Events = number of fluorescent nuclei.
MCF-7 15 nM VRL
150 nM VFL
control 4h 24h 48h 24+3 24+24 24+48
DNA histograms of vinorelbine and vinflunine in H292 cells Figure 4
DNA histograms of vinorelbine and vinflunine in H292 cells. detailed legend: DNA histograms of H292 cells treated 
with equitoxic concentrations of vinorelbine or vinflunine during 4, 24 and 48 hours and 24 and 48 h after drug removal. FL-2A 
= DNA content. Events = number of fluorescent nuclei.
H292 30 nM VRL
150 nM VFL
   : indicates a statistically significant higher amount of G2/M phase cells after VRL treatment compared to VFL, which coincided with a lower percentage of cells in G1 (*).
*
control 4h 24h 48h 24+3 24+24 24+48BMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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in ECV304 cells, the amount of S2 phase cells was signifi-
cantly lower after 48 h incubation with VRL compared to
VFL.
Even when VRL or VFL was removed after 24 h incubation,
not all cells could proceed in a normal cell cycle. 24 h after
the VRL or VFL incubation, a polyploid cell cycle was ini-
tiated. This was even more pronounced after 48 h in CAL-
27 because of the longer doubling time of this cell line.
Discussion
The strength of this study, thoroughly investigating the
radiosensitising and cell cycle effects of both VFL and VRL,
is the direct comparison that could be made between the
two semisynthetic vinca alkaloids. It is always difficult to
compare new results with formerly published results of
other research groups, because of the use of other tech-
niques, different experimental set-up, different cell lines,
concentrations, etc. Therefore, we used for both VFL and
VRL identical experimental conditions and equitoxic con-
centrations, and performed the experiments in the same
four human tumour cell lines. In this manner, the radio-
Table 2: Cell cycle distributions after 24 h incubation with equitoxic concentrations of VRL and VFL.
Cell line Contr 60 nM VFL Equitoxic conc. VRL 150 nM VFL Equitoxic conc. VRL
% G1
ECV304 39.1 ± 1.9 36.3 ± 2.2 (10 nM) 38.6 ± 2.8 15.0 ± 3.4a (30 nM) 10.1 ± 1.6a
CAL-27 56.4 ± 1.7 19.0 ± 1.0a (10 nM) 19.0 ± 3.4a 9.2 ± 1.1a (30 nM) 8.1 ± 1.5a
MCF-7 50.3 ± 1.5 19.1 ± 2.3a (8 nM) 18.0 ± 1.7a 11.3 ± 3.1a (20 nM) 10.9 ± 1.8a
H292 56.5 ± 0.9 39.3 ± 2.4a (15 nM) 25.6 ± 3.0a * 15.0 ± 3.0a (40 nM) 9.3 ± 2.6a
% S
ECV304 38.6 ± 1.6 44.1 ± 2.9 (10 nM) 37.1 ± 1.6 26.4 ± 3.2a (30 nM) 17.4 ± 1.7a
CAL-27 25.0 ± 1.1 33.3 ± 2.4 (10 nM) 31.0 ± 3.1 14.9 ± 1.9a (30 nM) 18.8 ± 2.6
MCF-7 26.2 ± 1.1 26.4 ± 1.4 (8 nM) 32.1 ± 2.0 29.7 ± 2.2 (20 nM) 32.1 ± 2.1a
H292 23.4 ± 0.5 23.5 ± 1.0 (15 nM) 20.0 ± 2.8 23.8 ± 2.3 (40 nM) 18.2 ± 1.8a
% G2/M
ECV304 20.2 ± 1.0 19.2 ± 1.0 (10 nM) 19.6 ± 2.8 50.2 ± 1.7a (30 nM) 62.5 ± 2.9a *
CAL-27 16.1 ± 0.7 30.4 ± 3.9a (10 nM) 32.8 ± 5.0a 55.4 ± 3.3a (30 nM) 53.7 ± 2.4a
MCF-7 20.3 ± 0.8 47.2 ± 6.1a (8 nM) 43.9 ± 1.6a 52.5 ± 4.7a (20 nM) 52.2 ± 1.2a
H292 17.8 ± 1.0 28.6 ± 1.3a (15 nM) 50.2 ± 5.0a * 53.2 ± 6.8a (40 nM) 65.9 ± 5.0a
Percentages of cells in the G1, S and G2/M phase of the cell cycle: after 24 h incubation with equitoxic concentrations of VRL and VFL; mean ± 
standard error.
a p < 0.05 compared to control
* p < 0.05 compared to the equitoxic concentration of VFL
Table 3: Percentages of cells in the G2/M phase of the cell cycle at different incubation times.
% of cells in G2/M
Cell line Control 4 h incub. 6 h incub. 16 h incub. 20 h incub. 24 h incub. 48 h incub.
VRL
ECV304 22.5 ± 1.3 37.7 ± 1.7a 45.4 ± 2.0a 58.2 ± 4.3a 53.9 ± 6.9a 58.7 ± 6.5a 46.4 ± 6.2
CAL-27 17.9 ± 1.0 33.3 ± 1.0a 40.3 ± 1.6a 66.9 ± 5.6a 61.9 ± 3.9a 64.3 ± 4.2a 23.7 ± 3.0b
MCF-7 18.1 ± 1.2 23.2 ± 1.0a 27.8 ± 1.5a 46.3 ± 3.6a * 39.6 ± 2.0a * 42.6 ± 2.6a 36.6 ± 2.3*
H292 18.2 ± 1.2 31.6 ± 3.6a 46.8 ± 5.9a 71.4 ± 1.7a 64.8 ± 4.4a 64.7 ± 7.5a 60.4 ± 3.1
VFL
ECV304 20.6 ± 1.4 32.7 ± 3.3a 37.9 ± 3.1a 64.1 ± 5.6a 44.9 ± 7.3a 48.7 ± 6.5a 42.4 ± 3.5
CAL-27 17.1 ± 1.5 33.7 ± 2.4a 40.9 ± 1.3a 61.2 ± 1.2a 63.0 ± 6.5a 62.7 ± 5.3a 21.3 ± 2.9b
MCF-7 18.7 ± 0.9 25.5 ± 1.8a 30.8 ± 2.2a 59.7 ± 1.0a 54.6 ± 3.2a 48.7 ± 5.9a 49.3 ± 2.9
H292 18.7 ± 1.1 37.8 ± 3.2a 38.5 ± 4.1a 65.4 ± 5.1a 66.0 ± 4.5a 69.4 ± 3.0a 65.7 ± 1.8
Percentages of cells in the G2/M phase of the cell cycle: at different incubation times with VRL and VFL; mean ± standard error.
a p < 0.05 compared to control
b p < 0.05 compared to 24 h incubation
* p < 0.05 compared to the equitoxic VFL concentrationBMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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sensitising effect of VFL could be placed in a somewhat
more identifiable context.
The radiosensitising effect of both semisynthetic vinca
alkaloids was dependent on the cell line tested and most
of the time also on the concentration used. When compar-
ing the VFL results to those of VRL, only small, statistically
insignificant differences were observed. In ECV304 cells,
VFL was slightly more radiosensitising than VRL. With a
VFL concentration around IC10 the calculated DEF was
1.57 (moderate synergism), while the DEF was 1.49 with
the approximately equitoxic VRL (IC15) concentration
Table 4: Percentages of cells in the G2/M phase of the cell cycle at different time points.
% of cells in G2/M
Cell line Control 24+0 h 24+3 h 24+24 h 24+48 h 24+72 h
VRL
ECV304 18.1 ± 0.9 70.3 ± 2.1a 56.0 ± 5.8b *3 2 . 6  ±  1 . 6 b 25.1 ± 0.8c 21.4 ± 1.5c
CAL-27 14.4 ± 1.2 56.0 ± 1.1a 30.7 ± 3.3b 23.2 ± 1.3b 21.5 ± 0.6 24.3 ± 2.3
MCF-7 17.8 ± 1.2 53.5 ± 0.9a 28.1 ± 4.4b 35.1 ± 3.5b 33.1 ± 0.3 28.6 ± 3.2
H292 13.3 ± 0.8 64.0 ± 4.2a 41.9 ± 1.2b 40.1 ± 1.5b 37.1 ± 1.4 27.1 ± 1.5c
VFL
ECV304 17.6 ± 0.9 47.3 ± 6.9a 28.2 ± 2.3b 31.8 ± 1.7b 27.8 ± 1.1 23.4 ± 1.7c
CAL-27 13.5 ± 0.5 55.7 ± 6.6a 31.8 ± 3.6b 24.5 ± 2.0b 25.0 ± 0.7 27.6 ± 1.0
MCF-7 17.2 ± 1.0 53.3 ± 5.8a 36.2 ± 3.8 27.8 ± 3.4b 27.3 ± 3.1 29.8 ± 3.3
H292 11.9 ± 1.4 65.7 ± 1.1a 39.5 ± 1.0b 41.3 ± 2.3b 41.0 ± 2.5 26.9 ± 3.9c
Percentages of cells in the G2/M phase of the cell cycle: at different time points after a 24 h incubation with VRL or VFL; mean ± standard error.
a p < 0.05 compared to control
b p < 0.05 compared to 24+0 h
c p < 0.05 compared to 24+24 h
* p < 0.05 compared to equitoxic VFL conc.
Table 5: Percentages of cells in the polyploid cell cycle.
Cell line Control 24 h 48 h 24+24 24+48
Percentage of cells in S2
VRL
ECV304 1.5 ± 0.2 5.5 ± 0.9a 18.5 ± 1.2a * 17.6 ± 2.3b 20.1 ± 0.9b
CAL-27 1.3 ± 0.1 5.6 ± 1.6 22.9 ± 1.5a 12.3 ± 1.4b 20.2 ± 0.9b
MCF-7 2.2 ± 0.5 2.9 ± 0.8 9.7 ± 3.9 4.4 ± 0.6 8.6 ± 0.5b
H292 1.4 ± 0.4 3.0 ± 1.0 7.9 ± 1.4a 3.4 ± 0.7 5.7 ± 0.9
VFL
ECV304 1.3 ± 0.2 7.6 ± 1.3a 22.4 ± 0.8a 12.6 ± 1.1b 16.2 ± 0.6b
CAL-27 1.7 ± 0.5 4.3 ± 1.0 21.8 ± 1.4a 11.8 ± 0.7 21.8 ± 0.8b
MCF-7 2.0 ± 0.3 2.8 ± 1.0 8.8 ± 1.6a 5.2 ± 0.4 10.6 ± 1.1b
H292 1.0 ± 0.2 2.9 ± 0.5a 7.1 ± 0.9a 3.6 ± 1.2 4.5 ± 0.5
Percentage of cells in (G2/M)2
VRL
ECV304 0.3 ± 0.0 1.2 ± 0.2a 12.2 ± 1.5a 9.8 ± 1.6b 10.2 ± 1.3b
CAL-27 0.4 ± 0.1 2.2 ± 0.6 37.4 ± 4.8a 4.8 ± 0.5b 6.1 ± 0.9b
MCF-7 0.5 ± 0.1 1.3 ± 0.3 2.1 ± 0.5 2.1 ± 0.7 3.4 ± 0.2b
H292 0.3 ± 0.1 1.1 ± 0.3 6.5 ± 1.0a 1.4 ± 0.2 2.2 ± 0.2b
VFL
ECV304 0.2 ± 0.0 0.8 ± 0.3 15.6 ± 0.8a 8.5 ± 1.3b 9.2 ± 1.1b
CAL-27 0.3 ± 0.1 2.1 ± 0.5 41.8 ± 4.9a 5.4 ± 0.4 7.5 ± 0.5b
MCF-7 0.5 ± 0.1 1.3 ± 0.2a 4.4 ± 0.8a 2.0 ± 0.5 4.4 ± 0.4b
H292 0.2 ± 0.0 1.2 ± 0.2a 7.0 ± 0.9a 1.9 ± 0.4 2.4 ± 0.3b
Percentages of cells in the polyploid cell cycle: at different incubation times with VRL or VFL and at different times after drug removal; mean ± 
standard error.
a p < 0.05 compared to control
b p < 0.05 compared to 24 h incubation
* p < 0.05 compared to equitoxic VFL conc.BMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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(slight synergism). However, in CAL-27 cells, IC45 con-
centrations of VRL already caused a more pronounced
radiosensitising effect (DEF = 1.92, synergistic effect)
compared to the equitoxic VFL concentration (DEF = 1.41,
only an additive effect). MCF-7 was the only cell line in
which the radiosensitising effect of VRL was not concen-
tration-dependent, in contrast to the results obtained with
VFL.
Regarding the cell cycle effects of VRL, a statistically signif-
icant concentration-dependent G2/M block was observed
after 24 h incubation (timepoint of radiation in the chem-
oradiation experiments). A significant G2/M block was
already seen after short incubation times (4 h), a maxi-
mum was reached after 16 h, followed by a significant
decrease in the amount of G2/M phase cells, resulting in
recycling of the cells in a normal or polyploid cell cycle.
After removal of VRL, cells also started recycling very rap-
idly (from 3 h after removal). After 24 h incubation and
especially after a prolonged continuous incubation (48
h), a polyploid population was clearly observed in
ECV304 and CAL-27 cells (p-value < 0.05 compared to
control), and less pronounced in the other cell lines. A
similar progress through the cell cycle was observed with
VFL treatment, with small (sometimes statistically signifi-
cant) cell line-dependent differences [30].
Our results obtained with VRL, confirmed and extended
the results already described in the literature. Four human
tumour cell lines, among which also a bladder and a
breast cancer cell line next to a lung and head & neck can-
cer cell line, were tested simultaneously. Edelstein et al.
investigated 2 human lung carcinoma cell lines (NCI-
H460 & A549) and concluded that 24 h incubation with
VRL before or after radiation resulted in a dose-dependent
potentiation of radiation, which was also cell cycle-
dependent, with maximal effect when cells were in the G2
phase of the cell cycle [26]. Also PC9 NSCLC cells were
sensitised to radiation by VRL, by causing accumulation of
cells in the G2/M phase of the cell cycle. Prolonged G2/M
accumulation concomitant with continuous polyploidi-
sation and increased susceptibility to induction of apop-
tosis may be associated with the cellular mechanism of
radiosensitisation produced by VRL in this cell line [27].
As described by Fukuoka et al., SBC-3 cells, human SCLC
cells, were also sensitised to radiation by VRL and a possi-
ble mechanism of the VRL-induced radiosensitisation
may in part, be associated with impairment of DNA repair
following radiation-induced DNA damage. It was hypoth-
esized that the disruption of microtubule integrity in SBC-
3 cells by VRL in part might inhibit p53 transport to the
nucleus, resulting in impairment of p53-mediated DNA
repair following radiation-induced DNA damage [28].
Erjala et al. investigated the concomitant use of vinorel-
bine and radiation in 8 head and neck squamous cell car-
cinomas (HNSCC). An additive effect (but not supra-
additivity) with radiation was noticed in all cell lines
tested [29]. The results described in the literature to date,
are cell line-dependent and several mechanisms for the
radiosensitising effect are proposed.
In view of our results, the observed G2/M block can be
related to the radiosensitising effect of VRL after 24 h incu-
bation followed by radiation. Also the contribution of the
polyploid population may be important. In ECV304 and
CAL-27, a statistically significant increase in S2 and (G2/
M)2 was already observed after 24 h incubation, although
in H292 and MCF-7 this was only the case after a pro-
longed incubation (48 h). Further investigation of the
polyploid population seems appropriate and of interest.
Possible contributions of DNA repair mechanisms or the
susceptibility to apoptosis warrants further study.
Overall, our study indicates that the radiosensitising
effects of VFL and VRL in vitro are comparable (p-value
comparing VRL with VFL never below 0.01), with small,
statistically insignificant cell line-related differences, and
indeed the cell cycle effects (G2/M block, polyploidisa-
tion) can be related to the observed radiosensitising
effects. Preclinical studies with VRL have prompted fur-
ther study of VRL as a radiosensitiser in the clinic. A Phase
I study of radiotherapy to the thorax combined with daily
VRL (4–6 mg/m2) administration (as a radiosensitiser) in
14 patients with locally advanced NSCLC resulted in 4
partial responses and 2 complete responses [38]. Also the
combined use of VRL with platinum compounds and irra-
diation has been shown to be feasible. The survival rates
achieved with this approach appeared to be superior to
those achieved with radiotherapy alone [39]. VFL has not
been studied in this setting. However, the advantages of
VFL over VRL are the following: (1) it has definite superior
antitumour activity against a wide range of experimental
tumour models compared to VRL, (2) it proved to be a far
less potent inducer of resistance than VRL, (3) it shows a
high level of synergy when combined with other chemo-
therapeutic agents, (4) it has anti-vascular and anti-ang-
iogenic effects at doses below the MTD, (5) it is extremely
well tolerated by patients used in a weekly schedule [40].
Combined with a reduced neurotoxicity related to VRL
(Table 6), these characteristics make VFL an interesting
addition to the currently available armamentarium of
chemotherapeutic agents, and, potentially an interesting
candidate for chemoradiation studies.
Conclusion
The radiosensitising effects of VFL and VRL were not sta-
tistically different from each other and were nearly always
cell line-specific and concentration-dependent. The cell
cycle effects could be related to the observed radiosensitis-
ing effects. Considering the more favourable toxicity pro-BMC Cancer 2008, 8:65 http://www.biomedcentral.com/1471-2407/8/65
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file of VFL, this agent might be more promising than VRL
for chemoradiation studies in the clinic.
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